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Abstract: Recent years have seen a dramatic increase in the amount and availability of data in the diverse 
areas of medicinal chemistry, making it possible to achieve significant advances in fields such as the 
design, synthesis and biological evaluation of compounds. However, with this data explosion, the storage, 
management and analysis of available data to extract relevant information has become even a more 
complex task that offers challenging research issues to Artificial Intelligence (AI) scientists. Ontologies 
have emerged in AI as a key tool to formally represent and semantically organize aspects of the real 
world. Beyond glossaries or thesauri, ontologies facilitate communication between experts and allow the 
application of computational techniques to extract useful information from available data. In medicinal 
chemistry, multiple ontologies have been developed during the last years which contain knowledge about 
chemical compounds and processes of synthesis of pharmaceutical products. This article reviews the 
principal standards and ontologies in medicinal chemistry, analyzes their main applications and suggests 
future directions. 
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The past several years have seen a sudden increase in the amount of publicly available data throughout 
different fields of the natural sciences. In areas that involve aspects of multiple disciplines, such as 
medicinal chemistry, this flood of data and knowledge is considered crucial to enable research through 
complex data-mining and knowledge discovery methods and develop new biologically active compounds 
for therapeutic use. However, this massive amount of data are frequently distributed over the Web and 
organized using different terminologies and formats, which constitutes an important barrier to process and 
analyze them in an integrated manner. As a consequence, retrieving relevant information from the 
available sources has become much more difficult. This situation demands the development and 
application of innovative strategies addressed to properly organize, retrieve and share the huge amount of 
available data in medicinal chemistry and its related fields. 
The word ontology is derived from Greek and refers to the philosophical study of the nature of being 
and existence. Ontologies were originally used by ancient Greek philosophers such as Aristotle in his 
Metaphysics [1] to name and classify the things they saw in the Universe and the relationships between 
them. More recently, in the 1990s, and especially since the Semantic Web was conceived [2], computer 
scientists have acquired the principles of philosophical ontology to represent the knowledge of some areas 
of interest (e.g. biology, medicine, chemistry, etc.) in a standard and machine-processable manner [3]. In 
computer science, ontologies are models for describing the world that consist of a set of types, properties, 
and relationships. An ontology can be graphically represented as a directed graph where nodes correspond 
to concepts, also known as entities or classes (e.g. “Biological agent”, “Specimen processing”, “Central 
nervous system deficit”), and arcs correspond to relationships between concepts (e.g. “is a”, “part of”). 
This graph-oriented representation enables the application of powerful techniques from the field of 
topological graph theory and other areas of mathematics that have been demonstrated to be useful in 
fields such as Medical Chemistry, Oncology, Neurology, Proteomics, Genomics, Microbiology, 
Technology, Sociology or Laws [4-8]. One example in Medicinal Chemistry are the 2D/3D protein 
graphs, used to predict protein biological functions [9-12]. Apart from its graphical representation, 
different languages have been proposed to represent ontologies in a machine-readable form [13]. 
Currently, the most popular and widely used ontology language is the Web Ontology Language (OWL) 
[14, 15], proposed by the World Wide Web Consortium (W3C) and based on the Resource Description 
Framework (RDF) [16]. OWL is the recommended language for building ontologies for the Semantic 
Web and provides computational reasoning capabilities across ontologies that can be used to infer new 
knowledge from existing data.  
In areas such as biology, medicine, chemistry and pharmacology, the necessity of structuring, sharing 
and reusing the huge amount of data about genes, proteins, diseases, molecular functions, etc. that has 
been generated during the last years, has led to the development of numerous ontologies that have 
demonstrated to be useful to support a variety of applications, such as data annotation [17] and integration 
[18], semantic search [19], terminology unification and standardization [20], information extraction [21], 
automated reasoning [22], development of expert systems [23], data mining [24] and prediction of 
protein-protein interactions [25]. In these fields, as the number and variety of available ontologies 
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continues steadily growing, so does the number of initiatives aimed to index, classify and organize them 
for researchers and knowledge engineers. Some of the largest and most referenced ontology repositories 
are the NCBO’s BioPortal [26], which contains more than 300 well-structured and controlled biomedical 
ontologies and terminologies, the EBI Ontology Lookup Service (OLS) [27] and the OBO Foundry portal 
[28], which contains a set of reference biomedical ontologies that adhere to the good ontology design 
principles proposed by the OBO Foundry initiative [29]. 
This review is intended to provide researchers and developers with a summary of the current ontology 
landscape for medicinal chemistry. To do so, we will present the most popular ontologies and reference 
terminologies in chemistry and drug development. We will also provide some future trends in the field. 
2 ONTOLOGIES IN MEDICINAL CHEMISTRY 
Medicinal chemistry is a multidisciplinary area that began to emerge about 150 years ago and that has 
been defined as “the applied science that is focused on the design and discovery of new chemical entities 
and their optimization and development as useful drug molecules for the treatment of disease processes” 
[30]. Traditionally most of the known information on the diverse areas of medicinal chemistry has been 
stored in books, journals and commercial databases. Nevertheless, during the last decade this situation 
changed dramatically. The discovery and application of new information and communication 
technologies and innovative computing strategies has dramatically increased the volume and availability 
of data about molecules, structures, proteins, sequences, drug targets and drug actions. Ontologies have 
been shown to be extremely useful to assist in the classification and organization of these data, to unify 
definitions and to facilitate data exchange, analysis and searching.  
Medicinal chemistry is a discipline that involves aspects of different areas such as chemistry, 
medicine or drug discovery and development. In fact, most medicinal chemists work with a team of 
scientists from different disciplines, including biologists, toxicologists, pharmacologists, theoretical 
chemists, microbiologists and biopharmacists [31]. As a consequence, a medicinal chemistry researcher 
who wants to use ontologies to enhance the usability of his data or a knowledge engineer aimed to build a 
system that manages medicinal chemistry information, should take into account a variety of ontologies 
from different fields. 
Keeping in mind that this review is intended to report the most relevant ontologies in medicinal 
chemistry, we will start examining the information provided by existing ontologies for the term 
“medicinal chemistry”. This term can be found in two popular biomedical ontologies: Medical Subject 
Headings (MeSH) and the National Cancer Institute (NCI) Thesaurus. MeSH [32] is a classification of 
terms created and maintained by the U.S. National Library of Medicine (NLM) for purposes of indexing 
and classifying medical literature. The NCI Thesaurus [33], developed by the U.S. National Cancer 
Institute, is an ontology providing broad coverage of the cancer domain, including cancer-related 
diseases, findings and abnormalities. Fig. 1 shows the location of “medicinal chemistry” both in the 
hierarchy of classes of MeSH and the NCI Thesaurus.  
In MeSH, the concept is represented using the term “Chemistry, Pharmaceutical”, which is classified 
as a children of “Pharmacology” and “Chemistry” categories, and as a superclass of “Drug Discovery”. 
The definition provided by MeSH is “Chemistry dealing with the composition and preparation of agents 
having pharmacologic actions or diagnostic use”.  
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The NCI Thesaurus provides a more comprehensive definition of this term. In this ontology, 
“Medicinal Chemistry” is a leaf node classified under the “Pharmacology” category that is defined as “A 
chemistry-based discipline, also involving aspects of biological, medical and pharmaceutical sciences. It 
is concerned with the invention, discovery, design, identification and preparation of biologically active 
compounds, the study of their metabolism, the interpretation of their mode of action at the molecular level 
and the construction of structure-activity relationships”. 
 
Fig. 1. Location of the concept “Medicinal Chemistry” in the hierarchy of classes of MeSH and the NCI Thesaurus. 
In the following sections, we will firstly present the most popular ontologies about chemical 
compounds. Then, we will review the ontologies addressed to classify pharmaceutical agents, or drugs. 
Finally, ontologies aimed to represent the essential entities and techniques in drug discovery, drug design, 
drug development and other related disciplines will be reported. 
2.1 Classification of chemical compounds 
Extracting, identifying, naming, classifying and exchanging information on compounds have been a 
major process of evolution of human civilization over tens of thousands of years. Initially, elements were 
classified by properties related to taste and smell, like “salty”, “sweet” or “bitter”. With the passing of 
time and in parallel with the discoveries made in chemistry, these classifications have become 
increasingly complex and detailed, giving rise to huge hierarchies of compounds and relationships 
between them.  
One of the first examples of using ontologies to classify chemical compounds was Medical Subject 
Headings (MeSH) [32], already mentioned in the previous section. The first official list of subject 
headings published by the NLM appeared in 1954 under the title Subject Heading Authority List. MeSH 
was initially developed for purposes of indexing and classifying medical literature, and nowadays it is 
used to facilitate searches in many resources. For example, the most popular query interfaces to MedLine 
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(e.g. PubMed [34]) use MeSH to support the retrieval of MedLine records in ways which improve the use 
of simple string searches. As it is shown in Fig. 2, MeSH is structured under 16 top-level categories that 
represent knowledge from different domains related to medicine. The “D” subtree (Chemicals and Drugs) 
contains chemical classes, individual compounds and biological concepts. Originally in English, MeSH 
has been translated into German, Japanese, Portuguese, Spanish, French, Russian, Polish, Romanian, 
Arabic, and other languages. The translations enable users not facile in English to find documents that are 
of sufficient potential interest to warrant reading. 
 
Fig. 2. Detail of the “Chemical and Drugs” subtree in MeSH. Screenshot from the MeSH Browser [35]. 
ChEBI (Chemical Entities of Biological Interest) [36-39] is the currently most comprehensive 
chemical compounds ontology. It is a freely available dictionary and ontological classification of 
molecular entities and groups, developed and maintained by the European Bioinformatics Institute (EBI) 
and focused on “small” chemical compounds. The term “molecular entity” refers to any constitutionally 
or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer, etc., 
identifiable as a separately distinguishable entity [40]. A group is a defined linked collection of atoms or a 
single atom within a molecular entity [41]. ChEBI provides a high quality, systematically annotated 
controlled vocabulary to promote the correct and consistent use of unambiguous biochemical terminology 
throughout the molecular biology databases at the EBI. It contains not only biochemical compounds, but 
also pharmaceuticals, agrochemicals, laboratory reagents, isotopes and subatomic particles. Since its first 
public release (21 July 2004), ChEBI has evolved to represent more than 30,000 molecular entities, 
groups and classes. The ontology structure is essentially a directed acyclic graph (DAG) and comprises 
three separate sub-ontologies: (1) Chemical Entity, which classifies molecular entities according to 
structure; (2) Role, which classifies entities on the basis of their role within an application, biological or 
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chemical context (e.g. pesticide, placebo, antioxidant, etc.); and (4) Subatomic Particle, which classifies 
particles smaller than atoms. An interesting application of ChEBI is ARISTO (Automatic Reduction of 
Ion Spectra To Ontology), a webtool that provides assignments to a subset of ChEBI using a mass 
spectrum of compounds as input [42]. Chemical ontologies such as CHEBI also facilitate new ways of 
knowledge discovery, for example, by extracting relationships between compound classes and related 
data from other domains, which are traditionally known as quantitative structure-activity relationships 
(QSAR) or quantitative structure–property relationships (QSPR) [5, 43-47].  
 
Fig. 3. Information about the drug “tamoxifen” in ChEBI. The figure shows a graphical representation of the drug and 
two different views (graph and tree) of its location in the hierarchy of classes. 
Fig. 3 shows some of the information provided by ChEBI for the chemical entity “tamoxifen”, which 
is a drug commonly used in breast cancer treatment. In ChEBI, each time a new compound is added, it 
must be assigned to the ontology by hand, which is a very labour-intensive and time-consuming process. 
A well-known effort aimed to automatically categorize small molecules instead of doing it by hand is 
the Chemical Ontology (CO) [48], based on the idea that small molecules can be classified by 
identifying their chemical functional groups using objective and computable criteria. CO has been built 
according to the functional groups assigned by the Checkmol software [49], a command-line utility 
program that is able to analyze an input molecule for the presence of various functional groups and 
structural elements. CO can be used to search chemical databases and identifying key functional groups 
responsible for biological activities. 
Another effort addressed to represent chemical structure and properties is the Chemical Information 
Ontology (CHEMINF). It has been conceived by several groups who have independently developed 
terminologies in the domain of chemical information. They have created a semantic chemistry working 
group [50] to develop CHEMINF, which is a unified, coherent OWL ontology to encode the terms, 
definitions, and logical axioms of chemical information entities [51]. The basic content of CHEMINF can 
be divided into named descriptors, named algorithms which calculate descriptors, and software libraries, 
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which contain software modules that implement algorithms. Fig. 4 shows the subclasses provided by 
CHEMINF ontology for the class "chemical descriptor". 
 
Fig. 4. Fragment of CHEMINF showing the subclasses of "chemical descriptor". Arrows represent hierarchical 
relationships between classes. 
An Ontology for Pharmaceutical Ligands has also been reported [52], which allows to bridge 
cheminformatics and bioinformatics by linking ligands to sequences. This ontology enables 
annotation-based searching of ligands and sequence similarity-based identification of ligands of next 
homologous receptors, and is key for further systematic chemogenomics exploration of previously well 
explored target families. 
Another relevant initiative is ChemTop [53], a top-domain, OWL-DL ontology that was created as an 
extract of BioTop [54] and that describes the foundational entities needed to characterize fenomena in the 
domain of chemistry and to interface both top and domain ontologies (e.g. EntireMolecularEntity, 
FattyAcid, NucleicAcid, etc.). ChemTop is based on the top ontology BFO (Basic Formal Ontology) [55] 
and on the relationships defined in RO (the Relation Ontology) [56]. As a consequence, it can be used as 
a top-level ontology for domain ontologies such as ChEBI.  
Other notable ontologies in the chemistry domain are REX [57] and FIX [58]. REX models 
physico-chemical processes occurring in the course of time. It includes both microscopic processes, 
involving molecular entities or subatomic particles, and macroscopic ones. Some biochemical processes 
from the popular Gene Ontology [59, 60] (GO Biological process) can be described as instances of REX. 
FIX complements REX and is an ontology of physico-chemical methods and properties. 
There are also some chemical ontologies that have been developed to represent specific subfields of 
chemistry. An example of ontology for representing lipid structures is LIPID MAPS [61, 62]. Another 
example is GlycO (the Glycomics Ontology) [63], which focuses on the glycoproteomics domain and 
models the structure and functions of glycans and glycoconjugates, the enzymes involved in their 
biosynthesis and modification, and the metabolic pathways in which they participate. 
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2.2 Classification of drugs 
Hospitals, pharmacies, research centers and other organizations use computer systems to record and 
process drug information. In order to ensure that these systems can exchange drug-related information 
efficiently and unambiguously, it is necessary to use a unified set of drug names. Many clinical 
information tasks can benefit from the use of a standard terminology for representing drug information, 
such as creation and management of electronic health records (EHR), communication between groups of 
experts, supporting interoperation between information systems, healthcare research, etc. [64]. 
RxNorm [65, 66] is a popular source created by the U.S. National Library of Medicine (NLM) to 
provide a single, standard, multipurpose terminology for representing medications, which has been built 
by aggregating, organizing and reconciling content from various source vocabularies. The first release of 
RxNorm date back to November 2004. Since then, it has been frequently used to navigate across drug 
vocabularies, exchange drug names and drug codes and as a reference to provide decision support in 
clinical environments. RxNorm provides links from clinical drugs to their active ingredients, drug 
components and related brand names. It also contains normalized names for clinical drugs and links their 
names to many drug terminologies regularly used in pharmacy management and drug interaction 
software. 
 
Fig. 5. Partial screenshot of RxNav showing the information provided by RxNorm for the drug Tamoxifen. 
To facilitate and enrich the use of RxNorm, the NLM provides several services which can be helpful 
to understand the RxNorm content, to facilitate the access to the RxNorm data and to make it easier to 
integrate the RxNorm vocabulary into specific applications or systems. One of these services is RxNav 
[67, 68], the RxNorm navigator, which is a Java application that allows to browse RxNorm and other 
sources, such as RxTerms and the National Drug File-Reference Terminology (NDF-RT) in a visually 
friendly and interactive manner. RxNav displays links from clinical drugs, both branded and generic, to 
their active ingredients, drug components and related brand names. Fig. 5 shows a screenshot of RxNav 
for the drug Tamoxifen. The NLM also provides an Application Programming Interface (API) for RxNav, 
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which allows to develop new applications based on data retrieved from the RxNorm database. Other 
useful services provided for RxNorm are RxTerms [69], MyMedicationList [70], MyRxPad [71] and 
RxMix. Current version of RxNorm is based on 11 different external source vocabularies, which are listed 
in Table 1. Apart from being part of RxNorm, some of these sources are widely-recognised vocabularies 
that are being used in a variety of medical applications around the world. 
Table 1. RxNorm data sources. 
Source Refs. 
Gold Standard Drug Database [72] 
Medi-Span Master Drug Data Base [73] 
Medical Subject Headings (MeSH) [32] 
Multum MediSource Lexicon [74] 
Micromedex RED BOOK [75] 
FDA National Drug Code Directory [76] 
FDA Structured Product Labels [77] 
FDB MedKnowledge (formerly NDDF Plus) [78] 
Veterans Health Administration National Drug File - Reference Terminology [79] 
SNOMED Clinical Terms (drug information) [80] 
Veterans Health Administration National Drug File [81] 
 
One of the sources that are part of RxNorm is Medical Subject Headings (MeSH) [32]. As explained 
in section 2.1, MeSH contains a subtree specifically addressed to classify “Chemicals and Drugs” into 16 
categories, such as: inorganic chemicals, organic chemicals, polycyclic compounds, enzymes and 
coenzymes, complex mixtures, etc. Fig. 6 shows the location of the drug Tamoxifen in the MeSH 
hierarchy. 
 
Fig. 6. Location of Tamoxifen in the MeSH tree. The root of the tree (“Organic Chemicals [D02]”) is one of the 16 
children of the top-level category “Chemicals and Drugs [D]”. Screenshot from the MeSH Browser [35]. 
A popular source that must also be also taken into account when looking for classifications of drugs is 
the National Drug File (NDF) [81] from the U.S. Veterans Health Administration (VHA), an 
organization that provides health care to more than 8 million veterans and dependants. The NDF is a 
nationally maintained medication terminology used to support the VHA information systems that includes 
information about drug costs, ingredients and inventory management [82]. It has been implemented as a 
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single-inheritance hierarchy of drug classes, drug products and national drug codes. A cross-reference file 
is used to list the ingredients of each product. 
After the VHA developed the NDF for representing drug terms in its clinical information systems, 
they released the National Drug File Reference Terminology (NDF-RT) [79], which is an enhancement 
of NDF that organizes the drug list into a formal representation, so that each drug has a computer-usable 
definition supporting data aggregation and retrieval. NDF-RT combines the NDF hierarchical drug 
classification with a multi-category reference model that includes orthogonal hierarchies for chemical 
structure, mechanisms of action, physiologic effects, clinical kinetics and therapeutic diseases, while 
preserving the existing VHA drug classes. NDF-RT was developed using description logics (DL) and is 
available for download in several formats, including XML and OWL. NDF-RT is part of the Federal 
Medication Terminologies (FMT) initiative and has studied within numerous academic and industry 
publications. 
Another relevant effort to classify drugs is the Anatomical Therapeutic Chemical (ATC) 
Classification System [83], controlled by the World Health Organization Collaborating Centre for Drug 
Statistics Methodology (WHOCC). In the ATC classification system, drugs are divided into 14 main 
groups according to the organ or system on which they act and their therapeutic, pharmacological and 
chemical properties. Each group represents a top-level category and is identified by an uppercase letter. 
Some of the ATC groups are: “A: Alimentary tract and metabolism”, “B: Blood and blood forming 
organs”, “C: Cardiovascular system” and “D: Dermatologicals”. The ATC categories are used in multiple 
databases related to different areas of medicinal chemistry, such as KEGG [84] and PharmGKB [85]. 
 
Fig. 7. Part of the hierarchy of classes of SNOMED-CT, showing some of the relevant classes in medicinal chemistry 
research. Note that there are some concepts that belong to more than one category (e.g. Analgesic is classified both as 
a "Pharmaceutical / biologic product" and a "Drug or medicament"). 
Another source that contains relevant information for medicinal chemistry professionals is the 
Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT) [80, 86], which is a 
comprehensive terminology system developed by the College of American Pathologists. It contains over 
395,000 terms and was formed by the merger, expansion, and restructuring of SNOMED RT (SNOMED 
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Reference Terminology) and the United Kingdom National Health Service Clinical Terms (also known as 
the Read Codes). SNOMED-CT contains a top-level category called “Pharmaceutical / biologic product” 
(see Fig. 7) that classifies pharmaceutical products into 93 different categories, such as: analgesic, anti-
infective agent, dietary product, gastrointestinal drug, nasal dosage form product, etc. In addition, it also 
contains a category “Chemical”, which classifies chemical substances both functionally and structurally, 
and a category “Drug or medicament”, with 53 subcategories that represent different kind of drugs (e.g. 
alcohol agent, central nervous system agent, nasal agent, renal agent, etc.). SNOMED-CT also contains 
terms to represent knowledge related to drug action and interactions (“Drug action” and “Drug 
interaction” classes). 
Apart from these general drug ontologies and reference terminologies, there are also some sources 
addressed to classify drugs used to treat specific diseases. An example in the cancer domain is the 
National Cancer Institute Thesaurus (NCI Thesaurus) [33], which is an ontology addressed to 
integrate molecular and clinical cancer-related information with a controlled terminology, providing a 
structured representation of key cancer-related concepts in fields such as drugs, therapies, pathways, 
cellular processes, etc. It is published monthly and provides information (definition, synonyms, etc.) on 
nearly 10,000 cancers and related diseases, 8,000 single agents and combination therapies, and a wide 
range of other topics related to cancer and biomedical research. The evolution and characterization of the 
NCI Thesaurus has been investigated by Gonçalves et al. [87]. Under the concept “Pharmacologic 
Substance” (id: C1254351), the NCI Thesaurus provides a wide set of technical definitions and synonyms 
for drugs or agents used to treat patients with cancer or conditions related to cancer. For an overview of 
the most relevant ontologies of drug discovery and design for complex diseases such as cancer, the reader 
is referred to previous work [88]. 
Another effort that requires attention is the research by Richesson et al. [89], who have studied the 
requirements and strategy for using an extraction of the NDF-RT terminology as a Pediatric Drug 
Ontology. They have stated that the NDF-RT ontology is too complex for routine tasks at the pediatric 
environment and that a subset of its concepts and relationships would be sufficient to support pediatric 
research analyses involving classes and properties of medications.  
2.3 Drug discovery, design and development 
Data produced with disparate methods from distinct organizations is heterogeneous. Standardization 
through knowledge engineering techniques enables the integration of diverse resources, increasing the 
total volume of data for analysis. In drug discovery, design and development, ontologies play an 
important role to provide a unified vision of different data sources, making it possible to integrate 
disparate data on a unified infrastructure and enable networked and collaborative research. In the previous 
sections, we have reviewed the ontologies that contain information about chemical compounds in general, 
and also those aimed to categorize drugs. Below, we will summarize recent efforts made to formalize 
knowledge related to drug discovery and design processes, paying special attention to those ontological 
efforts made to prevent adverse events caused by chemical substances such as drugs and vaccinations.  
 One of the best examples of ontology to support research in drug discovery is the Drug Discovery 
Investigations (DDI) ontology [90], which is aimed to add value to the information generated in the 
research and development stages of the drug pipeline by making the information easier to reuse, integrate, 
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curate, retrieve, and reason with. DDI is an application of the Ontology for Biomedical Investigations 
(OBI) [91], which is an integrated ontology for the description of investigations in the area of biology and 
medicine, to the area of drug discovery. DDI has been built on the basis of EXPO [92], an ontology of 
scientific experiments, and LABORS [93], which is a customized version of EXPO expressed in 
OWL-DL. One of the main applications of DDI is the support for the Robot Scientist Eve [94], which is 
designed to run automatic drug discovery investigations. 
Another successful example of bio-ontology that plays an essential role in drug development 
processes and applications is the well-known Gene Ontology (GO) [59, 60], whose aim is to address the 
need for consistent descriptions of gene products across species and databases. GO allows to describe 
attributes of gene products in three non-overlapping domains of molecular biology. It is composed by 
three ontologies, that describe gene products in terms of their related biological processes, cellular 
components and molecular functions in a species-independent way. An application of GO to the drug 
discovery domain is SuperTarget [95]. This resource integrates drug-related information associated with 
medical indications, adverse drug effects, drug metabolism, pathways and GO terms for target proteins. It 
contains a core dataset of more than 333,000 drug-target interactions, of which about 310,000 have 
binding affinity data. 
Yao et al. analyzed novel opportunities in drug discovery and emphasized the importance of 
conceptual standardization. They also suggested an overall design for an ontology to model drug 
discovery processes [96]. According to their work, the development of ontologies and terminologies 
enables the standardization of text mined information so that it can be used to model wider biological 
processes and inspire new drug targets and strategies. Andronis et al. reviewed the application of 
ontologies to the area of drug repurposing (DR) [97], which emerged as an alternative to the traditional 
drug development process. The authors explained that among the multitude of ontologies capturing 
biomedical information GO is among the most referenced ontologies in drug repurposing.  
The Translational Medicine Ontology (TMO) [98] is a high-level, patient-centric ontology that 
extends existing domain ontologies to bridge diverse areas of translational medicine including hypothesis 
management, discovery research, drug development and formulation, clinical research, and clinical 
practice. TMO has been developed by participants in the W3C Semantic Web for Health Care and Life 
Sciences Interest Group and member of the National Center for Biomedical Ontology (NCBO). 
Another area related to drug discovery and design that is increasingly being supported by ontologies is 
the early detection of unwanted or adverse effects of drugs, or adverse drug reactions (ADRs), which are 
a common cause for the rejection of drug candidates during clinical trial or withdrawal after approval. 
WHO’s definition of an adverse drug reaction, which has been in use for about 30 years, is “a response to 
a drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis, 
diagnosis or therapy of disease, or for modification of physiological function” [99]. The standard 
classification for ADRs is the Medical Dictionary for Regulatory Activities (MedDRA) terminology 
[100], which classifies adverse event information associated with the use of biopharmaceuticals and other 
medical products (e.g. medical devices and vaccines). MedDRA contains more than 90,000 terms 
structured in five levels of hierarchy and is employed by regulatory organizations worldwide (e.g. the 
U.S. Food and Drug Administration). Fig. 8 shows the top-level classes of MedDRA. A widely 
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recognized terminology in the field of the ADRs that was recently replaced by MedDRA is COSTART 
(Coding Symbols for Thesaurus of Adverse Reaction Terms) [101], developed by the FDA for coding, 
filing, and retrieving post-marketing adverse drug and biologic experience reports. MedDRA also 
provides the basis for other projects and innovative ideas. As an example, Zhichkin et al. believe that it is 
necessary to build an Adverse Reactions and Mechanisms ontology (ARM) [102], which would be a 
framework founded on the MedDRA terminology and consistent with the MedDRA general classification 
that would be addressed to link ADRs with biological mechanisms and functions, establishing 
correlations between them and allowing statistically meaningful inference from one to the other. 
 
Fig. 8. Top-level classes of MedDRA. 
The WHO-ART (World Health Organization - Adverse Reaction Terminology) [103] is a 
terminology that has been developed to serve as a basis for rational coding of adverse reaction terms and 
is widely used by both regulatory agencies and pharmaceutical manufacturers. Having into account that 
new drugs and new indications produce new adverse reaction terms, the structure of the terminology has 
been designed to be flexible enough to allow new entries to be incorporated whilst maintaining its 
structure and without losing previous information. Alecu et al. have reported a method to group ADR 
terms by means of SNOMED-CT [104]. They proposed a strategy to improve the WHO-ART structure by 
integrating the associative relationships included in SNOMED-CT.  
Another ontology that contains relevant knowledge about ADRs is the Ontology of Adverse Events 
(OAE) [105], previously named Adverse Event Ontology (AEO). It is a community-driven ontology that 
has been developed to standardize and integrate data on biomedical adverse events induced by different 
medical interventions such as administrations of vaccines, drugs, medical devices and nutritional 
products. OAE has been designed according to the OBO Foundry guidelines [29] such as openness, 
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collaboration, and use of a common shared syntax, and it is aligned with the Basic Formal Ontology 
(BFO) [55] and the Relation Ontology (RO) [56]. An ontology to improve adverse events reporting has 
also been developed. It is called the Adverse Event Reporting Ontology (AERO) [106] and is aimed at 
supporting clinicians at the time of data entry, increasing quality and accuracy of reported adverse events. 
As explained in [107], the main difference between AERO and AEO is that in AERO, the causality 
between the reported event and the medical intervention is not established. It describes the event that 
happened at the reporting time, when no association other than temporal can be established. However, in 
AEO, adverse events are defined as being induced by the medical intervention, where induced means that 
there is a chain of processes starting with the intervention and resulting in the adverse event. 
Current classifications of drugs and drug reactions have also been used to conceive semantic 
approaches and build new systems to facilitate drug prescription. Koutkias et al. have designed a 
knowledge-based framework to support adverse drug event prevention [108]. A decision support system 
for drug prescription in diabetes has also been reported [109]. Another example is the SemMed approach 
[110], aimed at reducing the risks caused by human factors in medication management. 
Finally, another noteworthy standard that can be useful in medicinal chemistry activities is Logical 
Observation Identifier Names and Codes (LOINC) [111], widely known as a universal code system 
for identifying laboratory and clinical observations. LOINC was initiated in 1994 by the Regenstrief 
Institute, an internationally respected non-profit medical research organization associated with Indiana 
University. Currently, it is considered the reference code set for laboratory test names in transactions 
between health care facilities, laboratories, laboratory testing devices, and public health authorities. In 
addition, LOINC is widely recognized and recommended for transmitting laboratory and clinical 
observations in HL7 messages [112]. 
Table 2 summarizes the ontologies and reference terminologies related to medicinal chemistry that 
have been reviewed in this work. For each source, the table contains its acronym, name, main scope, 
release version, number of terms and the most representative bibliographic references. 
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Table 2. Main reference ontologies and terminologies in medicinal chemistry. A hyphen (-) means undetermined or 
not applicable. 
Acronym Name Main scope Version Terms 
AERO [106] Adverse Event Reporting Ontology Adverse event reports 12/18/2012 388 
ARM [102] Adverse Reactions and Mechanisms 
Adverse drug 
reactions - - 




Drugs 2013 5,771 
ChEBI [36-39] Chemical Entities of Biological Interest Chemical entities 2013/01/07 (r99) 30,797 
CHEMINF [51] Chemical Information Ontology 
Chemical information 
entities 1.0 622 
ChemTop [53] ChemTop Chemistry 2009 110 
CO [48] Chemical Ontology Chemical entities - - 
COSTART [101] 
Coding Symbols for 
Thesaurus of Adverse 
Reaction Terms 
Adverse drug 
reactions 1995 1,641 
DDI [90] Drug Discovery Investigations 
Drug discovery 
research 0.9 645 
EXPO and LABORS 
[92, 93] EXPO and LABORS Scientific experiments 1.0 218 
GlycO [63] Glycomics Ontology Glycoproteomics 4.6.0.0 235 





GO [59, 60] Gene Ontology Gene products 2013/02/03 38,942 
LIPID MAPS [61, 62] LIPID MAPS Lipid structures 2010 10,774 
LOINC [111] Logical Observation Identifier Names and Codes 
Laboratory and 
clinical observations 236 171,399 
MedDRA [100] Medical Dictionary for Regulatory Activities 
Adverse drug 
reactions 12.0 69,389 
MeSH [32] Medical Subject Headings Medicine 2012-11-09-09 229,698 
NCI-T [33] National Cancer Institute Thesaurus Cancer 12.04e 93,411 
NDF [81] National Drug File Drugs 2009/08/07 26,866 
NDF-RT [79] National Drug File - Reference Terminology Drugs 2011/09/06 45,757 
AEO [105] Ontology of Adverse Events Adverse events 1.1.88 1,687 
OBI [91] Ontology for Biomedical Investigations 
Investigations in 
biology and medicine 2012/07/01 3,689 
OPL [52] Ontology for Pharmaceutical Ligands 
Pharmaceutical 
ligands - - 
PDO [89] Pediatric Drug Ontology Drugs in Pediatry - - 
REX [57] REX Physico-chemical processes 1.13 552 
RxNorm [65, 66] RxNorm Drugs 11AB_120305F 242,979 
SNOMED-CT [80] Systematized Nomenclature of Medicine-Clinical Terms Medicine 2011-07-31 395,036 
TMO [98] Translational Medicine Ontology 
Translational 
medicine 1.0.2 300 
WHO-ART [103] 
World Health Organization 
- Adverse Reaction 
Terminology 
Adverse drug 
reactions December 2005 2,085 
 
3 FUTURE CHALLENGES 
In spite of the dramatic advances that have been made during the last decade, the application of 
ontologies to the field of medicinal chemistry is far from being fully developed. There are many areas and 
problems in medicinal chemistry that can still benefit from the application of Artificial Intelligence 
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techniques such as ontologies and ontology-based systems. In addition, one of the main challenges which 
will have to be faced in the following years is the development of a solid infrastructure that allows to 
realise the Semantic Web vision in medicinal chemistry. 
One of the tasks the community will have to continue undertaking is ontology development. 
Currently, there are numerous ontologies and reference terminologies whose knowledge can be helpful to 
improve research processes in drug discovery and design. Nevertheless, they are still in an early phase. 
One of the major future challenges in pharmacology, medicinal chemistry and toxicology is the 
development of new ontologies to cover all the numerous subareas of medicinal chemistry and the 
intersection between fields such as chemistry and biology [21]. In order to ensure an adequate 
interoperability and scalability, these ontologies should be developed according to good ontology 
development principles [29]. The existence of multiple ontologies will also foster the development of 
ontology selection methods addressed to automatically choose the best ontology for a specific context or 
problem, instead of selecting it by hand, making it possible to build ontology-based systems that require a 
step of automatic knowledge reusing [113]. 
 
Fig. 9. Screenshot of TripleMap showing some of the information provided by LOOD resources for the drug 
Tamoxifen. 
Another strand of work will focus on the development and application of ontology-based techniques 
and the coordination of both academic and industry partners to connect all the available sources of drug 
data together to answer questions in medicinal chemistry. From the perspective of a researcher, the ideal 
data infrastructure should make it easy to search across different data sources containing data about drugs, 
clinical trials, diseases, pharmaceutical companies, traditional Chinese medicine, etc. in order to identify 
novel and meaningful correlations. As a consequence, initiatives aimed to connect all the isolated 
information related to medicinal chemistry available on the Web, such as the Linked Open Drug Data 
(LODD) project [114], are expected to attract attention over the next years. LOOD is a task force within 
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the World Wide Web Consortium’s (W3C) Health Care and Life Sciences Interest Group (HCLS IG) 
addressed to provide recommendations for the best practices of exposing pharmaceutical data in the Web 
by means of a set of technologies and conventions that are commonly referred to as Linked Data [115]. 
An example of application that provides a rich visual interface to explore and query current LOOD 
resources is TripleMap [116]. It is a web-based application that allows researchers to explore the 
relationships between biomedical entities that are stored in different datasets but connected through the 
LOOD infrastructure. Following with the previous examples about the drug Tamoxifen (see figures 3, 5 
and 6), Fig. 9 shows a screenshot of TripleMap with a graphical representation of some of the biomedical 
entities connected to Tamoxifen, such as side effects (leukopenia, optic neuritis, breast pain), enzymes 
(glutamine synthetase), possible disease targets (migraine, hypercholesterolemia), targets (estrogen 
receptor, epoxide hydrolase 2) and related research documents. 
A research area that it is also expected to play an essential role to link all the available semantic 
information about medicinal chemistry is ontology matching [117, 118], which is known as the process of 
finding the semantic relations between elements belonging to different ontologies. Given that different 
tasks or different points of view usually require different conceptualizations, utilizing a single ontology is 
neither always possible nor advisable. This can lead to the usage of different ontologies that might contain 
overlapping information (e.g. the same chemical compounds represented in two different ontologies). 
Ontology matching allows to find the correspondences between the elements of the different ontologies 
being used, ensuring an adequate exchange information between people, systems and organizations that 
use different standards to represent the same knowledge. 
Personalized medicine is another area where ontologies are expected to be crucial over the next years. 
There is an increasing interest within the medical community on the development and administration of 
personalized drugs, requiring the patient to receive the right drug at the right dose. Ontologies will 
facilitate the integration and analysis of traditionally separate data sets from early drug discovery through 
to patients in the clinical setting. 
4 CONCLUSIONS 
An important body of work has been done during the last decade regarding the formal representation of 
entities in chemistry and pharmacology. As a result, numerous ontologies and reference terminologies are 
available that allow to formalize knowledge about chemical compounds, drugs, drug discovery processes, 
adverse drug reactions, etc., facilitating the communication between groups of experts and also between 
information systems. Future prospects in this rapidly evolving arena look very promising. However, 
further work needs to be done in areas such as ontology development, ontology matching, ontology 
selection and ontology-based systems to facilitate the adoption of knowledge sources by the community 
and to foster the availability of innovative systems able to solve problems for medicinal chemistry 
professionals, according to the Semantic Web vision of people and computers working in cooperation.  
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